Project description DEENESFRITPL Paving the way for a novel diagnostic device for premature birth The World Health Organization estimates that there are around 15 million babies born prematurely every year. A birth is premature when it occurs before 37 completed weeks of gestation. Preterm birth complications significantly raise the risk of death in infants. Switzerland-based Pregnolia AG aims to be the first company to sell a diagnostic device that can determine the risk of premature birth based on stiffness of the uterine cervix, providing a solution for women undergoing routine pregnancy examinations. The EU-funded CervixCare project will scientifically and technologically characterise the gynaecological device by measuring its functions and gathering clinical evidence to validate its value. Show the project objective Hide the project objective Objective Pregnolia was founded in 2016, as a spin-off from the ETH Zurich and aims to be the first company selling a diagnostic device to determine the risk of Premature Birth (PTB) based on the measurements of cervical tissue stiffness to provide a solution that is usable by any woman undergoing routine pregnancy examinations. The goal of CervixCare is to scientifically and technologically characterize the gynaecological device in terms of measuring functions and gather clinical evidence to validate the diagnostic value of the medical device.The uniqueness of the system relies on its novel methodology to detect the risk of PTB, as there is no other commercially available solution based on the cervix stiffness. The proposed recruitment of an Innovation Associate in CervixCare will have significant impact on the business opportunities of Pregnolia by bringing in lacking expertise for the validation and certification of Pregnolia’s System into a diagnostic medical device. The envisaged grant will help to overcome the recruitment barriers of being a relatively unknown, small start-up enterprise that cannot compete with larger companies due to limited visibility, salary, recruitment budget and (perceived) career opportunities.CervixCare requires a multi-disciplinary scientist that understands the biomechanics for soft tissue, is able to model/simulate data by performing experiments and is able to use data for complex requirements for clinical validation and regulation of the diagnostic medical device. The main added value of the CervixCare project for the IA is the opportunity to pursue the transition from an academic environment focusing on basic research to a business environment focusing on developing competitive and cutting-edge products. Next to this, the IA will have the opportunity to influence and participate in the early stages of a new and innovative diagnostic device company. Fields of science medical and health sciencesclinical medicineobstetrics Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.2.3.2.2. - Enhancing the innovation capacity of SMEs Topic(s) INNOSUP-02-2019-2020 - European SME innovation Associate - pilot Call for proposal H2020-INNOSUP-2018-2020 See other projects for this call Sub call H2020-INNOSUP-2020-02 Funding Scheme CSA-LSP - Coordination and support action Lump sum Coordinator PREGNOLIA AG Net EU contribution € 159 250,00 Address WIESENSTRASSE 33 8952 Schlieren Switzerland See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Schweiz/Suisse/Svizzera Zürich Zürich Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost No data